Unnatural Products, a biotechnology firm pioneering orally-delivered macrocyclic peptides, has successfully closed a $45 million Series B financing round. The funding, led by The Venture Collective, is earmarked for advancing the company's proprietary drug discovery platform and its pipeline targeting previously undruggable disease pathways. This financial milestone follows a significant licensing agreement with Novartis, underscoring the company's growing momentum in the biopharmaceutical industry.
A Novel Approach to Drug Discovery
The company focuses on macrocyclic peptides, a unique class of therapeutics that combines the advantages of both small molecules and biologic drugs. These molecules possess the high selectivity of biologics while retaining the potential for cell permeability and oral administration, a key advantage. This approach allows Unnatural Products to address complex intracellular protein interactions that drive many chronic and age-related diseases.
At the core of its strategy is an integrated discovery platform that merges advanced computational design with automated chemistry and high-throughput biological testing. This sophisticated system enables the rapid engineering and optimization of synthetic macrocyclic peptides at a large scale. The platform is designed to efficiently move from initial discovery hits to promising drug candidates ready for further development.
Strategic Funding to Accelerate Growth
The $45 million financing was led by The Venture Collective, with notable participation from new investors argenx and Droia Ventures. They were joined by existing backers, including Merck Global Health Innovation Fund, Artis Ventures, and First Spark Ventures. This robust support from both new and current investors signals strong confidence in the company's technology and long-term vision.
According to CEO Cameron Pye, the capital will accelerate the development of the company's pipeline and advance its lead programs toward the clinic. The funding is crucial for progressing lead candidates through IND-enabling studies and positioning the company for clinical entry. This investment allows the firm to build a broader therapeutic pipeline than is typically possible at this early stage.
Building on Strong Industry Partnerships
This funding announcement comes just a month after Unnatural Products secured a major licensing deal with pharmaceutical giant Novartis. The collaboration, focused on developing therapies for undruggable cardiovascular targets, could be worth up to $1.7 billion in milestones. The agreement also includes up to $100 million in upfront and pre-IND milestone payments, providing significant non-dilutive capital.
The Novartis partnership is one of several key collaborations, with others established with industry leaders like Merck, BridgeBio, and argenx. Nicholas Shekerdemian, a founding partner at The Venture Collective, noted the platform's potential to unlock new therapeutic opportunities. These alliances validate the broad applicability of the company's macrocyclic peptide technology across various therapeutic areas.
With the successful closure of its Series B financing, Unnatural Products is strongly positioned to advance its mission of drugging the undruggable. The fresh capital, combined with powerful industry collaborations, provides the resources needed to mature its innovative platform and pipeline. The company is now on a clear path to potentially deliver a new class of oral medicines for challenging diseases.